Shulan Zhang1, Jing Luo2, Ziyan Wu2, Dirk Roggenbuck3, Peter Schierack3, Dirk Reinhold4, Ji Li5, Xiaofeng Zeng1, Fengchun Zhang1, Jiaming Qian5, Yongzhe Li1. 1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China. 2. Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Shanxi, China. 3. Institute of Biotechnology, Faculty of Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany. 4. Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 5. Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
Abstract
OBJECTIVES: There is an increasing need to identify reliable biomarkers for distinguishing Crohn's disease (CD) from other gastrointestinal disorders sharing similar clinical and pathological features. This study aimed at evaluating the diagnostic potential of antibodies to zymogen granule glycoprotein GP2 (aGP2) in a large, well-defined Chinese cohort with a special focus on their role in discriminating CD from intestinal Behçet's disease (BD) and intestinal tubercolosis (ITB). METHODS: A total of 577 subjects were prospectively enrolled, including 171 patients with CD, 208 patients with ulcerative colitis (UC), 71 with BD, 57 with ITB and 70 healthy controls (HC). aGP2 and anti-Saccharomyces cerevisiae antibodies (ASCA) were determined by ELISA. Perinuclear antineutrophil cytoplasmic antibodies were tested by indirect immunofluorescent assay. RESULTS: aGP2 IgG and IgA levels were significantly elevated in patients with CD compared with those in patients with UC, intestinal BD, and ITB and HC. Conversely, ASCA IgG levels were not different between CD and intestinal BD patients, whereas ASCA IgA levels did not discriminate CD from intestinal BD and ITB patients. aGP2 IgA and IgG displayed a better assay performance (larger areas under the curve) over ASCA IgA and IgG in differentiating CD from disease controls (P<0.05). ASCA IgA did not discriminate CD from disease controls. aGP2 IgA and/or IgG was significantly associated with penetrating disease (B3) and ileal CD (L1) (P<0.05), whereas ASCA IgA and/or IgG was not. CONCLUSIONS: In comparison with ASCA, aGP2 distinguishes CD from intestinal BD or ITB as disease controls more efficiently, aiding in the differential diagnosis of IBD.
OBJECTIVES: There is an increasing need to identify reliable biomarkers for distinguishing Crohn's disease (CD) from other gastrointestinal disorders sharing similar clinical and pathological features. This study aimed at evaluating the diagnostic potential of antibodies to zymogen granule glycoprotein GP2 (aGP2) in a large, well-defined Chinese cohort with a special focus on their role in discriminating CD from intestinal Behçet's disease (BD) and intestinal tubercolosis (ITB). METHODS: A total of 577 subjects were prospectively enrolled, including 171 patients with CD, 208 patients with ulcerative colitis (UC), 71 with BD, 57 with ITB and 70 healthy controls (HC). aGP2 and anti-Saccharomyces cerevisiae antibodies (ASCA) were determined by ELISA. Perinuclear antineutrophil cytoplasmic antibodies were tested by indirect immunofluorescent assay. RESULTS:aGP2 IgG and IgA levels were significantly elevated in patients with CD compared with those in patients with UC, intestinal BD, and ITB and HC. Conversely, ASCA IgG levels were not different between CD and intestinal BD patients, whereas ASCA IgA levels did not discriminate CD from intestinal BD and ITBpatients. aGP2 IgA and IgG displayed a better assay performance (larger areas under the curve) over ASCA IgA and IgG in differentiating CD from disease controls (P<0.05). ASCA IgA did not discriminate CD from disease controls. aGP2 IgA and/or IgG was significantly associated with penetrating disease (B3) and ileal CD (L1) (P<0.05), whereas ASCA IgA and/or IgG was not. CONCLUSIONS: In comparison with ASCA, aGP2 distinguishes CD from intestinal BD or ITB as disease controls more efficiently, aiding in the differential diagnosis of IBD.
Authors: Polychronis Pavlidis; Lars Komorowski; Bianca Teegen; Christos Liaskos; Andreas L Koutsoumpas; Daniel S Smyk; Carlo Perricone; Maria G Mytilinaiou; Winfried Stocker; Alastair Forbes; Dimitrios P Bogdanos Journal: Clin Chem Lab Med Date: 2016-02 Impact factor: 3.694
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Dirk Roggenbuck; Dirk Reinhold; Thomas Wex; Alexander Goihl; Ulrike von Arnim; Peter Malfertheiner; Thomas Büttner; Tomas Porstmann; Silvia Porstmann; Bodo Liedvogel; Dimitrios P Bogdanos; Martin W Laass; Karsten Conrad Journal: Clin Chim Acta Date: 2010-12-31 Impact factor: 3.786
Authors: Mandy Sowa; Rafał Kolenda; Daniel C Baumgart; Johann Pratschke; Maria Papp; Tamas Tornai; Jaroslaw Suchanski; Dimitrios P Bogdanos; Maria G Mytilinaiou; Jutta Hammermann; Martin W Laass; Karsten Conrad; Christoph Schramm; Andre Franke; Dirk Roggenbuck; Peter Schierack Journal: Front Immunol Date: 2018-08-28 Impact factor: 7.561
Authors: Konstantinos Gkiouras; Maria G Grammatikopoulou; Xenophon Theodoridis; Eirini Pagkalidou; Evangelia Chatzikyriakou; Anna G Apostolidou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios Petrou Bogdanos Journal: World J Gastroenterol Date: 2020-01-14 Impact factor: 5.742